Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
СтатьяКлинические рекомендацииПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kindler Hedy L, Ismaila Nofisat, Bazhenova Lyudmila, Chu Quincy, Churpek Jane E, Dagogo-Jack Ibiayi, Bryan Darren S, Drazer Michael W, Forde Patrick, Husain Aliya N, Sauter Jennifer L, Rusch Valerie, Bradbury Penelope A, Cho B C John, de Perrot Marc, Ghafoor Azam, Graham David L, Khorshid Ola, Lebensohn Alexandra, White Julie, Hassan Raffit
Аннотация
PURPOSE: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM).
METHODS: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS: The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.
RECOMMENDATIONS: Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
METHODS: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advocacy experts to conduct an updated literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2016 through 2024. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS: The literature search identified 110 additional relevant studies to inform the evidence base for this guideline.
RECOMMENDATIONS: Evidence-based recommendations were developed for surgical cytoreduction, immunotherapy, chemotherapy, pathology, and germline testing in patients with PM.Additional information is available at www.asco.org/thoracic-cancer-guidelines.